BRPI0517983A - uso de corticosteróide em associação com diurético e antiácido para tratamento de estenose vascular e prevenção de reestenose vascular - Google Patents

uso de corticosteróide em associação com diurético e antiácido para tratamento de estenose vascular e prevenção de reestenose vascular

Info

Publication number
BRPI0517983A
BRPI0517983A BRPI0517983-1A BRPI0517983A BRPI0517983A BR PI0517983 A BRPI0517983 A BR PI0517983A BR PI0517983 A BRPI0517983 A BR PI0517983A BR PI0517983 A BRPI0517983 A BR PI0517983A
Authority
BR
Brazil
Prior art keywords
diuretic
vascular
antacid
prevention
treatment
Prior art date
Application number
BRPI0517983-1A
Other languages
English (en)
Inventor
Flavio Ribichini
Corrado Vassanelli
Original Assignee
Uni Degli Studi Del Piemonte O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni Degli Studi Del Piemonte O filed Critical Uni Degli Studi Del Piemonte O
Publication of BRPI0517983A publication Critical patent/BRPI0517983A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE CORTICOSTERóIDE EM ASSOCIAçAO COM DIURéTICO E ANTIáCIDO PARA TRATAMENTO DE ESTENOSE VASCULAR E PREVENçAO DE REESTENOSE VASCULAR. Uso de pelo menos um corticosterólde em associação com pelo menos um diurético e pelo menos um antiácido na preparação de um medicamento para o tratamento de estenose vascular e a prevenção de reestenose vascular. Preferivelmente, o corticosteróide, o diurético e o antiácido são administrados oralmente. Preferivelmente, o corticosteróide é prednisona, o diurético é furosemida e o antiácido é omeprazole.
BRPI0517983-1A 2004-11-03 2005-11-02 uso de corticosteróide em associação com diurético e antiácido para tratamento de estenose vascular e prevenção de reestenose vascular BRPI0517983A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000760A ITTO20040760A1 (it) 2004-11-03 2004-11-03 Uso di un corticosteroide in associazione ad altri principi attivi per il trattamento della stenosi vascolare e la prevenzione della restenosi vascolare
PCT/IB2005/003271 WO2006048736A1 (en) 2004-11-03 2005-11-02 Use of a corticosteroid in association with a diuretic and an antacid for the treatment of vascular stenosis and the prevention of vascular restenosis

Publications (1)

Publication Number Publication Date
BRPI0517983A true BRPI0517983A (pt) 2008-10-21

Family

ID=36051437

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517983-1A BRPI0517983A (pt) 2004-11-03 2005-11-02 uso de corticosteróide em associação com diurético e antiácido para tratamento de estenose vascular e prevenção de reestenose vascular

Country Status (6)

Country Link
EP (1) EP1814557A1 (pt)
BR (1) BRPI0517983A (pt)
CA (1) CA2586212A1 (pt)
IT (1) ITTO20040760A1 (pt)
RU (1) RU2007120522A (pt)
WO (1) WO2006048736A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
DK3354276T3 (da) 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
EP2127639A1 (en) * 2008-05-26 2009-12-02 Universiteit Utrecht Holding B.V. Corticosteroid containing liposomes for treatment of cardiovascular diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
PE20020082A1 (es) * 2000-04-12 2002-02-21 Novartis Ag Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1)

Also Published As

Publication number Publication date
EP1814557A1 (en) 2007-08-08
CA2586212A1 (en) 2006-05-11
RU2007120522A (ru) 2008-12-10
WO2006048736A1 (en) 2006-05-11
ITTO20040760A1 (it) 2005-02-03

Similar Documents

Publication Publication Date Title
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
NO20064054L (no) Terapeutiske kombinasjoner av atypiske antipsykotika med corticotropine frigivningsfaktor antagonister
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
AR054371A1 (es) Metodos y composiciones para manejo de desordenes psicoticos
DE69826644D1 (de) Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
WO2007149406A8 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
DE60332629D1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
BRPI0418742A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
BR0315316A (pt) Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
TR200102107T2 (tr) Tümör nekroz faktör antagonistleri ve endometriozda kullanımları.
ATE382356T1 (de) Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
EP1719515A3 (en) Glycyrrhizin or derivatives thereof for treating or preventing togavirus infections
JP2007119497A5 (pt)
WO2004041191A3 (en) Methods for the treatment, prevention and management of macular degeneration
DE60320034D1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
WO2004041190A3 (en) Composition for the treatment of macular degenration
AR038858A1 (es) Combinacion
BRPI0517132A (pt) regime de cladribina para o tratamento da esclerose múltipla
BRPI0415651A (pt) métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica
BRPI0606528A8 (pt) composição para uso no fabrico de medicamentos de tratamento da infertilidade masculina e uso da mesma
BRPI0518700B8 (pt) combinação contendo vegf-trap, 5-fluorouracila e ácido folínico

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired